234 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
IONS Ionis Pharmaceuticals, Inc. $48.21 $6.62B N/A
Article Searches
AveXis Inc.: Buy at the High? https://www.fool.com/investing/2017/07/18/avexis-inc-buy-at-the-high.aspx?source=iedfolrf0000001 Jul 18, 2017 - Stellar clinical-trial results have pushed AveXis Inc. stock to an all-time high. Is the stock still a buy at recent prices, or should you wait for a pullback?
Here's Why the Best Is Yet to Come for Ionis Pharmaceuticals, Inc. https://www.fool.com/investing/2017/04/13/heres-why-the-best-is-yet-to-come-for-ionis-pharma.aspx?source=iedfolrf0000001 Apr 13, 2017 - A pipeline of drugs has this biotech poised for further success.
Highpower International: 2016 EV Lithium-Ion Battery Sales Doubled, Earnings Soared 60% https://seekingalpha.com/article/4059163-highpower-international-2016-ev-lithium-ion-battery-sales-doubled-earnings-soared-60-percent?source=feed_tag_editors_picks Mar 31, 2017 - Highpower International delivered a bullish Q4 and full-year EPS report today driven by a 40%+ increase in Li-ion battery sales.Full-year net income grew 60% while gross margins increased 2.8% to 21.9
Why the Ionis Spinoff Will Be a Win for Long-Term Investors https://www.fool.com/investing/2017/04/18/why-the-ionis-spinoff-will-be-a-win-for-long-term.aspx?source=iedfolrf0000001 Apr 18, 2017 - Ionis keeps doing what it's good at: developing new drugs and setting up future revenue streams
2 Pharma Buyout Targets That May Surprise You https://www.fool.com/investing/2017/06/27/2-biopharma-buyout-targets-that-may-surprise-you.aspx?source=iedfolrf0000001 Jun 27, 2017 - When the M&A bonanza picks up again, Biogen and Bristol-Myers Squibb may be the first to go. Here's why.
Spinraza's Fast Start Puts Ionis on a Path to Profit https://www.fool.com/investing/2017/04/25/spinrazas-fast-start-puts-ionis-on-a-path-to-profi.aspx?source=iedfolrf0000001 Apr 25, 2017 - A strong start for the spinal muscular atrophy drug Spinraza could help Ionis Pharmaceuticals deliver pro forma profit in 2017.
Biogen Inc. Earnings: New Drug Sparks Life https://www.fool.com/investing/2017/04/26/biogen-inc-earnings-new-drug-sparks-life.aspx?source=iedfolrf0000001 Apr 26, 2017 - Spinraza launch is off to a good start.
3 Stocks With Promising, Amazon-Like Growth Potential https://www.fool.com/investing/2017/06/10/3-stocks-with-promising-amazon-like-growth-potenti.aspx?source=iedfolrf0000001 Jun 10, 2017 - Amazon has made investors rich over the past 20 years. These three companies could have similar potential.
Why Alnylam Pharmaceuticals, Inc. Skyrocketed and Ionis Pharmaceuticals Inc Sank Today https://www.fool.com/investing/2017/09/20/why-alnylam-pharmaceuticals-inc-skyrocketed-and-io.aspx?source=iedfolrf0000001 Sep 20, 2017 - One biotech's phase 3 success means competition for the other.
Better Buy: Ionis Pharmaceuticals, Inc. vs. bluebird bio https://www.fool.com/investing/2017/04/27/better-buy-ionis-pharmaceuticals-inc-vs-bluebird-b.aspx?source=iedfolrf0000001 Apr 27, 2017 - Which of these two pioneering biotech companies are the best place for new money today?

Pages: 1234567...24

<Page 2>